Core Insights - Day One Biopharmaceuticals (DAWN) has entered into a definitive agreement with Servier for the acquisition of all outstanding shares at $21.50 each, valuing the deal at approximately $2.5 billion [1][7] Group 1: Acquisition Details - The acquisition will enable Servier to add Ojemda, DAWN's first marketed drug, which received accelerated FDA approval in 2024 for treating relapsed or refractory pediatric low-grade glioma (pLGG) [2] - The deal is expected to close in the second quarter, with Servier planning to finance the transaction through existing cash and investments [3] Group 2: Financial Performance - Following the acquisition announcement, DAWN's stock price surged nearly 66%, and the stock has increased by 127% year-to-date compared to the industry's 4% growth [4] Group 3: Strategic Rationale - Servier's interest in DAWN aligns with its 2030 goal to develop innovative treatments across various therapeutic areas, including oncology [6] - Ojemda reported sales of $155.4 million for the full year 2025, reflecting a 172% year-over-year increase, with projected sales for 2026 estimated between $225 million and $250 million [6] Group 4: Portfolio Expansion - In addition to Ojemda, the acquisition will enhance Servier's oncology portfolio with two early-stage antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301, which are currently in separate early-stage studies [8] - This acquisition is part of Servier's broader strategy, which includes previous deals in the oncology space, such as licensing agreements with Black Diamond Therapeutics and Ideaya Biosciences [9]

Summary of Day One Biopharmaceuticals FY Conference Call Company Overview - **Company**: Day One Biopharmaceuticals (NasdaqGS:DAWN) - **Core Product**: OJEMDA, approved for pediatric low-grade glioma [3][4] Financial Performance - **2025 Revenue**: Over $155 million, marking the first full year of OJEMDA's launch - **Year-over-Year Growth**: 170% increase in revenue [4] - **Q4 2025 Revenue**: Over $52 million, with a 37% growth quarter-over-quarter [4] - **2026 Revenue Guidance**: Projected between $225 million and $250 million, indicating approximately 50% growth year-over-year [30] Key Metrics for Growth - **New Patient Starts (NPS)**: Increased by 25% in the second half of 2025 compared to the first half [12] - **Duration of Therapy**: Mean duration approximately 17 months, median duration 19 months, indicating strong patient retention [13] Pipeline Developments - **Emi-Le Program**: A B7-H4-targeted ADC for adenoid cystic carcinoma, with data expected mid-2026 [6] - **DAY301 Program**: A PTK7-targeted ADC, initial clinical data anticipated in the second half of 2026 [6][41] OJEMDA Launch Insights - **Frontline Enrollment**: Expected completion in the first half of 2026 [5] - **Second Line Use**: Increasing familiarity among physicians is driving more second-line usage of OJEMDA [15][21] - **Education and Data**: Ongoing education for KOLs and physicians is crucial for increasing patient starts and therapy persistence [22][27] Clinical Data and Impact - **Treatment-Free Interval**: Median time to next therapy after OJEMDA is approximately 43 months, with nearly 80% of children remaining off therapy after one year [25][27] - **Physician Engagement**: Positive data from ASCO and other conferences are expected to enhance physician confidence and patient management [23][28] Strategic Focus - **Durable Growth Story**: The company aims to establish OJEMDA as a standard of care in second-line treatment for pediatric low-grade glioma [60] - **Employee Commitment**: Acknowledgment of the team's efforts in executing the company's strategy and managing acquisitions effectively [60] Conclusion - Day One Biopharmaceuticals is positioned for significant growth driven by the successful launch of OJEMDA and a robust pipeline. The focus on education, data dissemination, and patient management strategies will be critical in achieving the projected revenue targets and expanding market presence.

Financial Data and Key Metrics Changes - For the full year 2025, the company reported net product revenue of $155.4 million, representing a 172% increase year-over-year [6][35] - The fourth quarter net product revenue reached $52.8 million, reflecting a 37% sequential growth over the third quarter [21][35] - The company ended 2025 with over $440 million in cash and no debt, providing a strong financial foundation [9][38] Business Line Data and Key Metrics Changes - OJEMDA remains the primary revenue driver, with over 4,600 total prescriptions for the year, marking an increase of more than 180% compared to 2024 [6][22] - The company achieved double-digit sequential quarterly growth throughout 2025, with fourth quarter prescriptions exceeding 1,300, representing an 11% growth quarter-over-quarter [21][22] Market Data and Key Metrics Changes - The company anticipates global expansion for OJEMDA, with regulatory approvals being prepared for ex-U.S. markets, including Europe [8] - Coverage rates for pediatric low-grade glioma (PLGG) remain above 95%, with over 90% of patients approved on the first request [24] Company Strategy and Development Direction - The company aims to solidify OJEMDA as the second-line standard of care in PLGG, with a focus on driving new patient starts and optimizing treatment persistence [23][25] - The acquisition of Mersana Therapeutics is seen as a strategic move to enhance the pipeline, particularly with the Emi-Le program targeting adenoid cystic carcinoma [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, reiterating guidance for OJEMDA net product revenue of $225 million to $250 million [6][38] - The company is focused on establishing a strong scientific basis for OJEMDA's use in frontline settings through ongoing clinical trials [7][18] Other Important Information - The company reported a median duration of therapy for commercial PLGG patients trending towards 19 months, indicating robust treatment persistence [47] - The three-year follow-up data from the FIREFLY-1 trial demonstrated a 53% objective response rate, reinforcing the clinical efficacy of OJEMDA [12][18] Q&A Session Summary Question: How does the company maintain and improve persistency for OJEMDA? - Management highlighted that persistency is currently strong, with median therapy duration trending towards 19 months, and identified opportunities for improvement through physician education and patient support programs [45][47] Question: What are the expectations for the updated Emi-Le data? - Management indicated that substantial data will be shared mid-year, focusing on antitumor activity and safety, which will support discussions with the FDA regarding accelerated clinical development [52][56] Question: What are the early trends for Q1 2026? - Management reiterated confidence in the guidance for 2026, noting that demand remains strong in Q1, although specific details about the current quarter were not disclosed [61][63] Question: Can the company break down the time to next treatment analysis further? - Management acknowledged the importance of understanding treatment patterns and indicated that ongoing analyses will provide insights into patient responses post-progression [64][66] Question: What is the expected response rate for Emi-Le in adenoid cystic carcinoma? - Management emphasized the need for a robust data set that clearly delineates the performance of Emi-Le compared to existing therapies, which currently have poor response rates [82][86]

Financial Data and Key Metrics Changes - In 2025, the company reported net product revenue of $155.4 million, representing a 172% year-over-year increase [6][35] - The fourth quarter net product revenue reached $52.8 million, reflecting a 37% sequential growth over Q3 [21][35] - The company ended 2025 with approximately $441 million in cash and no debt, providing a strong financial foundation [9][38] Business Line Data and Key Metrics Changes - OJEMDA remains the primary revenue driver, with over 4,600 total prescriptions in 2025, marking an increase of over 180% compared to 2024 [6][22] - The company achieved double-digit sequential quarterly growth throughout 2025, with Q4 prescriptions exceeding 1,300, representing an 11% growth quarter-over-quarter [21][22] Market Data and Key Metrics Changes - The company anticipates global expansion for OJEMDA, with regulatory approvals being prepared for ex-U.S. markets, including Europe [8] - Coverage rates for pediatric low-grade glioma (PLGG) remain above 95%, with over 90% of patients approved on the first request [24] Company Strategy and Development Direction - The company aims to solidify OJEMDA as the second-line standard of care in PLGG, with a focus on driving new patient starts and optimizing treatment persistence [23][25] - The acquisition of Mersana Therapeutics is seen as a strategic move to enhance the pipeline, particularly with the Emi-Le program targeting adenoid cystic carcinoma [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, reiterating guidance for OJEMDA net product revenue of $225 million-$250 million [6][38] - The company is focused on establishing a strong scientific basis for OJEMDA's use in frontline settings through ongoing clinical trials [7][18] Other Important Information - The company reported a decline in total costs and operating expenses to $286 million for the full year 2025, down from $348 million in 2024 [36] - The company has maintained a favorable gross and net profile for OJEMDA, with gross and net margins expected to be in the range of 16%-19% in 2026 [38] Q&A Session Summary Question: How does the company maintain and improve persistency for OJEMDA? - Management highlighted that current persistency is robust, with a median duration of therapy trending towards 19 months, and identified opportunities to improve persistency through targeted physician education and patient support programs [45][47] Question: What are the expectations for the updated Emi-Le data? - Management indicated that substantial data will be shared mid-year, focusing on antitumor signals and safety datasets to support registration discussions with the FDA [52][56] Question: What are the early trends for 2026? - Management reiterated confidence in 2026 revenue guidance, noting strong demand in Q1, although specific quarterly details were not disclosed [61][63] Question: Can the company provide insights on treatment patterns for patients? - Management discussed the potential for treatment breaks and retreatment based on patient stability, emphasizing the importance of clinical decisions over radiographic assessments [78][80] Question: What is the expected response rate for Emi-Le in ACC? - Management stated that they aim for a robust dataset demonstrating significant efficacy and safety for Emi-Le, particularly in a population with urgent therapeutic needs [82][86]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported net product revenue of $155.4 million, representing a 172% increase year-over-year, with double-digit sequential quarterly growth throughout the year [5][34] - In Q4 2025, net product revenue reached $52.8 million, reflecting a 37% sequential growth over Q3 [20][34] - The company ended 2025 with approximately $441 million in cash and no debt, providing a strong financial foundation for future growth [9][38] Business Line Data and Key Metrics Changes - OJEMDA remains the primary revenue driver, with over 4,600 total prescriptions for the year, marking an increase of over 180% compared to 2024 [5][21] - The company achieved a median duration of therapy trending towards 19 months for commercial PLGG patients, indicating strong persistency [47] Market Data and Key Metrics Changes - The company anticipates global expansion for OJEMDA, with regulatory approvals being prepared for markets outside the U.S., including Europe [8] - Coverage rates for PLGG remain above 95%, with over 90% of patients approved on the first request, facilitating quick therapy initiation [23] Company Strategy and Development Direction - The company aims to solidify OJEMDA as the second-line standard of care in pediatric low-grade glioma (PLGG) and is focused on driving new patient starts and optimizing treatment persistence [22][24] - The acquisition of Mersana Therapeutics is seen as a strategic move to enhance the pipeline, particularly with the Emi-Le program targeting adenoid cystic carcinoma [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, reiterating guidance for OJEMDA net product revenue of $225 million to $250 million [5][38] - The company is optimistic about the potential of OJEMDA to become the standard of care in the second-line setting, supported by positive clinical data and physician confidence [22][24] Other Important Information - The company is advancing multiple pipeline programs, including DAY301 and Emi-Le, which target significant unmet medical needs in oncology [27][30] - The three-year follow-up data from the FIREFLY-1 trial demonstrated a 53% objective response rate for OJEMDA, reinforcing its clinical efficacy [12][18] Q&A Session Summary Question: How does the company maintain and improve persistency for OJEMDA? - Management highlighted that current persistency is strong, with median therapy duration trending towards 19 months, and identified opportunities to enhance persistency through targeted patient support programs and physician education [47][48] Question: What are the expectations for the upcoming Emi-Le data? - Management indicated that they expect to present substantial data supporting the move into registrational trials, focusing on the antitumor activity and safety profile of Emi-Le [52][54] Question: What early trends are observed in Q1 2026? - Management noted that demand remains strong in Q1, with confidence in achieving the reiterated revenue guidance for the year [62][63] Question: Can the company provide insights on the time to next treatment analysis? - Management explained that the analysis shows that many patients continue therapy despite radiographic progression, emphasizing the importance of clinical signs over imaging results in treatment decisions [66][68] Question: What is the expected response rate for Emi-Le in ACC? - Management stated that they aim for a robust data package that clearly delineates the performance of Emi-Le compared to existing therapies, which have poor response rates [85][86]

FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted ...

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or th ...

Core Viewpoint - Day One Biopharmaceuticals is set to report its financial results and corporate progress for Q4 and full-year 2025 on February 24, 2026, highlighting its commitment to developing targeted therapies for life-threatening diseases, particularly in pediatric cancer [1]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on addressing the unmet needs in pediatric cancer treatment [3]. - The company aims to redefine cancer drug development and improve outcomes for patients of all ages from the moment of diagnosis [3]. Group 2: Pipeline and Development - Day One's pipeline includes tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate targeting the B7-H4 protein, currently in clinical development for adenoid cystic carcinoma (ACC) [4]. - The recent acquisition of Mersana Therapeutics enhances Day One's capabilities in developing targeted cancer treatments [4]. Group 3: Communication and Accessibility - A live conference call and webcast will be available for stakeholders to access financial results and corporate updates [2]. - An archived version of the webcast will be accessible for 30 days post-event, ensuring continued engagement with investors and the public [2].

Core Insights - Day One Biopharmaceuticals reported preliminary 2025 net product revenue of $155.4 million, reflecting a 172% year-over-year growth, with 2026 U.S. net product revenue projected to be between $225 million and $250 million [1][6] - The company is set to present its corporate progress and priorities for 2026 at the J.P. Morgan Healthcare Conference on January 12, 2026 [1][6] 2025 OJEMDA Commercial Performance - OJEMDA net product revenue for Q4 2025 was approximately $52.8 million, contributing to the full-year revenue of $155.4 million, marking a 37% quarter-over-quarter growth and a 172% year-over-year growth [6] - The increase in revenue was driven by rising patient demand, with prescription volumes reaching 1,394 in Q4 2025 [6] 2026 Corporate Priorities and Key Milestones - The company aims to achieve 2026 OJEMDA net product revenue guidance, focusing on increasing persistency and driving new patient starts to establish OJEMDA as the standard of care in second-line pediatric low-grade glioma (pLGG) [6] - Plans include global expansion of OJEMDA beyond the U.S. through partnerships [6] - Completion of enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial for first-line pLGG is expected in the first half of 2026, with data readout anticipated in mid-2027 and potential approval in 2028 [6] - The Emi-Le program is set to deliver Phase 1 clinical data by mid-2026, progressing towards registration [6] - Initial data from the Phase 1a clinical trial for DAY301, a PTK7-targeted antibody drug conjugate, is expected in the second half of 2026 [6] Financial Position - As of December 31, 2025, prior to the acquisition of Mersana, Day One had approximately $441.1 million in cash, cash equivalents, and short-term investments [5]

Core Insights - Day One Biopharmaceuticals, Inc. is focused on developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, addressing a significant unmet need in therapeutic development [3][4]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company based in Brisbane, California [4]. - The company aims to redefine cancer drug development for all ages, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3]. Group 2: Upcoming Events - Dr. Jeremy Bender, the CEO of Day One, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. Pacific Time [1]. - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-event [2]. Group 3: Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4]. - The company collaborates with leading clinical oncologists, families, and scientists to identify and develop important cancer treatments [4].